Core Viewpoint - The article discusses the investigation by Monteverde & Associates PC into the proposed acquisition of iTeos Therapeutics, Inc. by Concentra Biosciences, LLC, questioning the fairness of the deal. Group 1: Transaction Details - Concentra Biosciences, LLC plans to acquire iTeos Therapeutics, Inc. for $10.047 in cash per share [1] - The acquisition includes a non-transferable contingent value right, which entitles shareholders to 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] Group 2: Legal Context - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering money for shareholders [1] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2]
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)